FR22C1061I1 - OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF - Google Patents

OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF

Info

Publication number
FR22C1061I1
FR22C1061I1 FR22C1061C FR22C1061C FR22C1061I1 FR 22C1061 I1 FR22C1061 I1 FR 22C1061I1 FR 22C1061 C FR22C1061 C FR 22C1061C FR 22C1061 C FR22C1061 C FR 22C1061C FR 22C1061 I1 FR22C1061 I1 FR 22C1061I1
Authority
FR
France
Prior art keywords
oligosaccharides
conjugates
aminooxy group
aminooxy
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR22C1061C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of FR22C1061I1 publication Critical patent/FR22C1061I1/en
Application granted granted Critical
Publication of FR22C1061I2 publication Critical patent/FR22C1061I2/en
Active legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/738Cross-linked polysaccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549Sugars, nucleosides, nucleotides or nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02Acyclic radicals, not substituted by cyclic structures
    • C07H15/04Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405Glucanases
    • C12N9/2408Glucanases acting on alpha -1,4-glucosidic bonds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/04Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04012Sphingomyelin phosphodiesterase (3.1.4.12)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102Alpha-glucosidase (3.2.1.20)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022Alpha-galactosidase (3.2.1.22)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01076L-Iduronidase (3.2.1.76)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
FR22C1061C 2007-01-18 2022-12-15 OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF Active FR22C1061I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88547107P 2007-01-18 2007-01-18
PCT/US2008/051429 WO2008089403A2 (en) 2007-01-18 2008-01-18 Oligosaccharides comprising an aminooxy group and conjugates thereof

Publications (2)

Publication Number Publication Date
FR22C1061I1 true FR22C1061I1 (en) 2023-02-03
FR22C1061I2 FR22C1061I2 (en) 2023-11-17

Family

ID=39473250

Family Applications (1)

Application Number Title Priority Date Filing Date
FR22C1061C Active FR22C1061I2 (en) 2007-01-18 2022-12-15 OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF

Country Status (19)

Country Link
US (5) US8759501B2 (en)
EP (5) EP2457919B1 (en)
JP (6) JP5999867B2 (en)
CN (2) CN101631794B (en)
CA (1) CA2675968C (en)
CY (2) CY1119954T1 (en)
DK (3) DK2457919T3 (en)
ES (3) ES2744574T3 (en)
FR (1) FR22C1061I2 (en)
HR (3) HRP20130744T1 (en)
HU (3) HUE045046T2 (en)
IL (3) IL243117B2 (en)
LT (2) LT2457920T (en)
NL (1) NL301210I2 (en)
NO (2) NO2457920T3 (en)
PL (3) PL2121713T3 (en)
PT (3) PT2457920T (en)
SI (2) SI2457920T1 (en)
WO (1) WO2008089403A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723296B2 (en) * 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
WO2008013735A2 (en) * 2006-07-21 2008-01-31 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Methods for conjugation of oligosaccharides or polysaccharides to protein carriers through oxime linkages via 3-deoxy-d-manno-octulsonic acid
PL2121713T3 (en) 2007-01-18 2013-11-29 Genzyme Corp Oligosaccharides comprising an aminooxy group and conjugates thereof
WO2009024977A2 (en) * 2007-08-20 2009-02-26 Protalix Ltd. Saccharide-containing protein conjugates and uses thereof
EP3608330B1 (en) * 2008-12-16 2022-11-09 Genzyme Corporation Synthetic intermediates for preparing oligosaccharide-protein conjugates
ES2576853T3 (en) 2009-07-03 2016-07-11 Inserm - Institut National De La Santé Et De La Recherche Médicale Compounds directed to the mannose 6-phosphate receptor independent of cations
NZ597600A (en) * 2009-07-27 2014-05-30 Lipoxen Technologies Ltd Glycopolysialylation of non-blood coagulation proteins
RU2744370C2 (en) * 2009-07-27 2021-03-05 Баксалта Инкорпорейтед Blood coagulation protein conjugates
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
EP2585108A4 (en) * 2010-06-24 2016-04-13 Univ Kansas Conjugates comprising an n-oxime bond and associated methods
WO2012082635A1 (en) * 2010-12-13 2012-06-21 Ancora Pharmaceuticals, Inc. Synthetic oligosaccharide group a streptococcus
US9732333B2 (en) 2011-01-20 2017-08-15 Protalix Ltd. Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells
AU2014218854B2 (en) 2013-02-20 2019-01-24 Valerion Therapeutics, Llc Methods and compositions for treatment of Pompe disease
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
TWI821227B (en) 2017-12-22 2023-11-11 美商健臻公司 Biomarkers of methotrexate-induced immune tolerance
AU2019377869A1 (en) * 2018-11-08 2021-05-27 Kaleido Biosciences, Inc. Oligosaccharide compositions and methods of use thereof
EP4100064A1 (en) 2020-02-07 2022-12-14 Novartis AG Targeted plasma protein degradation
JP2023512783A (en) 2020-02-08 2023-03-29 ジェンザイム・コーポレーション Compositions and methods for treating Pompe disease
BR112022025314A2 (en) 2020-06-14 2023-01-03 Genzyme Corp COMPOSITIONS AND METHODS FOR TREATMENT OF LATE ONset POMPE DISEASE

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4701521A (en) * 1978-07-17 1987-10-20 The Trustees Of Boston University Method of effecting cellular uptake of molecules
DE2940845B1 (en) 1979-10-09 1980-06-26 Ford Werke Ag Centrifugal pump seal, in particular for cooling water pumps in motor vehicles
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US5066789A (en) * 1988-09-30 1991-11-19 Neorx Corporation Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages
US5206370A (en) * 1989-02-24 1993-04-27 Johnson Matthey, Inc. Certain pyridyl hydrazines and hydrazides useful for protein labeling
IL93432A (en) 1989-02-24 1994-02-27 Johnson Mathey Inc Hydrazines and hydrazides, their conjugates with macromolecules and such conjugates labelled with metal ions
US5212298A (en) * 1989-08-16 1993-05-18 Monsanto Company Method for producing synthetic N-linked glycoconjugates
US5280113A (en) * 1989-08-16 1994-01-18 Monsanto Company Method for producing synthetic N-linked glycoconjugates
US5324663A (en) * 1990-02-14 1994-06-28 The Regents Of The University Of Michigan Methods and products for the synthesis of oligosaccharide structures on glycoproteins, glycolipids, or as free molecules, and for the isolation of cloned genetic sequences that determine these structures
US5583042A (en) * 1990-04-16 1996-12-10 Neose Pharmaceuticals, Inc. Apparatus for the synthesis of saccharide compositions
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
EP0513332A4 (en) * 1990-11-14 1993-03-17 Cargill, Incorporated Conjugates of poly(vinylsaccharide) with proteins for the stabilization of proteins
AU1580292A (en) * 1991-03-13 1992-10-21 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Increasing the therapeutic efficiency of macrophage-targeted therapeutic agents by up-regulating the mannose lectin on macrophages
CA2101918A1 (en) 1991-03-18 1992-09-19 Samuel Zalipsky Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
FR2721612B1 (en) * 1994-06-23 1996-08-09 Idm New oligoside derivatives, their preparation process and their applications.
US6132764A (en) * 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US6118045A (en) * 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
AUPO190596A0 (en) * 1996-08-26 1996-09-19 Alchemia Pty Ltd Oligosaccharide synthesis
PT959905E (en) * 1997-01-21 2010-02-05 Sanofi Pasteur Polysaccharide-peptide-conjugates
US5952516A (en) 1997-05-08 1999-09-14 Genzyme Corporation Cationic amphiphiles containing multiplesteroid lipophilic groups
IL135578A0 (en) * 1997-10-29 2001-05-20 Genzyme Corp Compositions and methods for treating lysosomal storage disease
US6287857B1 (en) 1998-02-09 2001-09-11 Genzyme Corporation Nucleic acid delivery vehicles
US6538117B1 (en) * 1999-08-10 2003-03-25 The Scripps Research Institute Programmable one-pot oligosaccharide synthesis
JP2004505885A (en) * 1998-08-19 2004-02-26 ノース アメリカン ワクチン, インコーポレイテッド Immunogenic β-propionamide linked polysaccharide-protein conjugates useful as vaccines produced using N-acryloylated polysaccharides
US6399575B1 (en) * 1998-11-10 2002-06-04 Auburn University Methods and compositions for targeting compounds to the central nervous system
EP1035137A1 (en) * 1999-03-12 2000-09-13 Pasteur Merieux Serums Et Vaccins Method for the reductive amination of polysaccharides
EP1183230A1 (en) * 1999-06-08 2002-03-06 La Jolla Pharmaceutical Valency platform molecules comprising aminooxy groups
US6770468B1 (en) * 1999-09-14 2004-08-03 Genzyme Glycobiology Research Institute, Inc. Phosphodiester-α-GlcNAcase of the lysosomal targeting pathway
US6537785B1 (en) * 1999-09-14 2003-03-25 Genzyme Glycobiology Research Institute, Inc. Methods of treating lysosomal storage diseases
WO2001060412A2 (en) 2000-02-15 2001-08-23 Genzyme Corporation Modification of biopolymers for improved drug delivery
US6749865B2 (en) * 2000-02-15 2004-06-15 Genzyme Corporation Modification of biopolymers for improved drug delivery
AU2001280035A1 (en) 2000-07-26 2002-02-05 Ramot University Authority For Applied Research And Industrial Development Ltd. Intracellular delivery system for protein phosphatases and other polypeptides
WO2002016384A2 (en) * 2000-08-18 2002-02-28 Massachusetts Institute Of Technology Apparatus and methods for the automated synthesis of oligosaccharides
US6676963B1 (en) * 2000-10-27 2004-01-13 Barnes-Jewish Hospital Ligand-targeted emulsions carrying bioactive agents
US7001994B2 (en) * 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
US7723296B2 (en) * 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
ATE384736T1 (en) * 2001-04-30 2008-02-15 Zystor Therapeutics Inc SUB-CELLULAR TARGETING OF THERAPEUTIC PROTEINS
US7629309B2 (en) * 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7560424B2 (en) * 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
JP2004514410A (en) 2001-05-07 2004-05-20 スプラテック ファーマ インコーポレイティド Ligands for enhancing oral and CNS supply of biological agents
BR122015016314B8 (en) 2001-07-16 2021-05-25 Genzyme Corp method of preparing an acyclic compound, method of preparing an amine compound, method of preparing a sphingosine-type compound and method of preparing a ceramide-type compound
EP2292271A3 (en) 2001-10-10 2011-09-14 BioGeneriX AG Remodelling and glycoconjugation of an antibody
US7265084B2 (en) * 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US6835831B2 (en) 2001-11-26 2004-12-28 Genzyme Corporation Diastereoselective synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors
US6800472B2 (en) * 2001-12-21 2004-10-05 Genzyme Glycobiology Research Institute, Inc. Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester α-N-acetyl glucosimanidase
US6905856B2 (en) * 2001-12-21 2005-06-14 Genzyme Glycobiology Research Institute, Inc. Soluble GlcNAc phosphotransferase
AU2003222568B2 (en) 2002-01-11 2009-05-07 Bioasis Technologies, Inc. Use of P97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
TWI295483B (en) 2002-01-31 2008-04-01 Sumitomo Chemical Co 3-5 group compound semiconductor, process for producing the same, and compound semiconductor element using the same
EP1585817B1 (en) * 2002-02-20 2009-09-02 The General Hospital Corporation Conjugates comprising a biodegradable polymer and uses therefor
US6916802B2 (en) 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
CA2495242A1 (en) 2002-09-11 2004-03-25 Fresenius Kabi Deutschland Gmbh Hasylated polypeptides, especially hasylated erythropoietin
EP1400533A1 (en) * 2002-09-11 2004-03-24 Fresenius Kabi Deutschland GmbH HASylated polypeptides, especially HASylated erythropoietin
US20050026823A1 (en) * 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
CA2525236C (en) 2003-06-20 2015-03-24 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
WO2005014035A2 (en) 2003-08-08 2005-02-17 Novo Nordisk Health Care Ag Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
US7691826B2 (en) 2003-08-12 2010-04-06 Lipoxen Technologies Limited Polysialic acid derivatives
US7442372B2 (en) * 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
EP1525890A1 (en) 2003-10-02 2005-04-27 Complex Biosystems GmbH Protein-Proteophore complexes
US7176185B2 (en) * 2003-11-25 2007-02-13 Tsrl, Inc. Short peptide carrier system for cellular delivery of agent
WO2005072778A2 (en) * 2004-01-29 2005-08-11 Biosynexus, Inc. Use of amino-oxy functional groups in the preparation of vaccines conjugates
EP1720405A4 (en) 2004-02-06 2008-08-27 Biomarin Pharm Inc Manufacture of highly phosphorylated lysosomal enzymes and uses thereof
SI1740204T1 (en) 2004-04-01 2018-07-31 Chiesi Farmaceutici S.P.A. Medicinal use of alpha-mannosidase
US8017151B2 (en) * 2004-09-07 2011-09-13 Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center Amphiphilic polymer-protein conjugates and methods of use thereof
WO2006108052A2 (en) 2005-04-06 2006-10-12 Genzyme Corporation Peg and polysialic lysosomal enzyme conjugates via acid labile linkers for therapeutic targeting
WO2008089339A2 (en) 2007-01-18 2008-07-24 Genzyme Corporation Oligosaccharide conjugates for cellular targeting
PL2121713T3 (en) 2007-01-18 2013-11-29 Genzyme Corp Oligosaccharides comprising an aminooxy group and conjugates thereof
EP3608330B1 (en) * 2008-12-16 2022-11-09 Genzyme Corporation Synthetic intermediates for preparing oligosaccharide-protein conjugates

Also Published As

Publication number Publication date
US20150050262A1 (en) 2015-02-19
LT2457919T (en) 2019-09-25
JP2018109194A (en) 2018-07-12
IL199925A (en) 2017-09-28
FR22C1061I2 (en) 2023-11-17
PT2121713E (en) 2013-06-25
NO2457920T3 (en) 2018-03-24
NO2022056I1 (en) 2022-12-09
US20200010825A1 (en) 2020-01-09
IL199925A0 (en) 2010-04-15
CN101631794A (en) 2010-01-20
ES2656314T3 (en) 2018-02-26
HUE036140T2 (en) 2018-06-28
EP2121713B1 (en) 2013-06-12
PL2457920T3 (en) 2018-03-30
IL243117B2 (en) 2023-03-01
JP2017052962A (en) 2017-03-16
WO2008089403A2 (en) 2008-07-24
PL2121713T3 (en) 2013-11-29
ES2417146T3 (en) 2013-08-06
US20170014520A1 (en) 2017-01-19
JP2020185011A (en) 2020-11-19
SI2457920T1 (en) 2018-02-28
EP4293112A3 (en) 2024-03-13
HRP20180076T1 (en) 2018-02-23
EP3597655A1 (en) 2020-01-22
DK2457920T3 (en) 2018-01-22
EP4293112A2 (en) 2023-12-20
IL243117A (en) 2016-01-31
PL2457919T3 (en) 2019-12-31
JP2022137232A (en) 2022-09-21
JP5999867B2 (en) 2016-09-28
US20100047225A1 (en) 2010-02-25
CN102978185B (en) 2015-02-11
CY1122452T1 (en) 2021-01-27
EP3597655B1 (en) 2023-08-02
JP6039625B2 (en) 2016-12-07
DK2457919T3 (en) 2019-09-16
IL222792A0 (en) 2012-12-31
US10907142B2 (en) 2021-02-02
JP6309592B2 (en) 2018-04-11
CA2675968C (en) 2019-05-21
SI2457919T1 (en) 2019-10-30
HUE045046T2 (en) 2019-12-30
HUS2200055I1 (en) 2023-01-28
NL301210I1 (en) 2022-12-21
IL243117B (en) 2022-11-01
CN102978185A (en) 2013-03-20
US8759501B2 (en) 2014-06-24
WO2008089403A3 (en) 2008-11-13
PT2457920T (en) 2018-01-23
HRP20130744T1 (en) 2013-10-11
CY1119954T1 (en) 2018-12-12
HRP20191562T1 (en) 2019-11-29
US20220204963A1 (en) 2022-06-30
EP2457920A1 (en) 2012-05-30
JP2010516257A (en) 2010-05-20
LT2457920T (en) 2018-02-12
CA2675968A1 (en) 2008-07-24
EP2457920B1 (en) 2017-10-25
DK2121713T3 (en) 2013-06-24
CN101631794B (en) 2013-01-02
EP2121713A2 (en) 2009-11-25
US9469850B2 (en) 2016-10-18
EP2457919B1 (en) 2019-06-05
JP2015078360A (en) 2015-04-23
EP2457919A1 (en) 2012-05-30
ES2744574T3 (en) 2020-02-25
NL301210I2 (en) 2023-02-02
PT2457919T (en) 2019-09-20

Similar Documents

Publication Publication Date Title
FR22C1061I2 (en) OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF
BRPI0923473A2 (en) simulated cigarette device and system
DK1973564T3 (en) VACCINE COMPREHENSIVE STREPTOCOCCUS PNEUMONIAE-Capsule POLYSACCHARIDE CONJUGATE
DK2444807T3 (en) MONO AND DINITROPYRAZOLHAPTEN CONJUGATES
DK3207941T6 (en) PROCEDURES AND COMPOSITIONS BASED ON DIPHTHERITOXIN-INTERLEUKIN-3 CONJUGATES
ZA200802225B (en) Interleukin-1 conjugates and uses thereof
ATE447991T1 (en) MEDICINAL DELIVERY DEVICE
FR2944571B1 (en) ANTICHOCK SUPPORT ASSEMBLY AND DETECTOR COMPRISING THE SAME
DE602007011305D1 (en) COFFEE AND TEEDOSER SYSTEM
TWI349428B (en) Class ab amplifier
GB0515122D0 (en) Intolerance testing device and system
DE112008001073A5 (en) Fumigation device and system
FR2909105B1 (en) DRYING CABINET.
ITMI20080183A1 (en) AMPLIFIER AND SYSTEM DEVICE USING THE DEVICE
GB0701081D0 (en) Intolerance testing device and system
SI2121713T1 (en) Oligosaccharides comprising an aminooxy group and conjugates thereof
FR2916702B1 (en) CONSOLE NAME AND ESCAMOTABLE.
BRPI0912444A2 (en) "mounting arrangement, wall part and connecting unit"
NL1034526A1 (en) Emoticon device.
ES1061833Y (en) TRANSFORMABLE STATIC PEDALEO DEVICE IN ARMCHAIR.
ITMO20050146A1 (en) AMPLIFIER DEVICE.
ES1059871Y (en) ALIGNMENT DEVICE FOR SHAFT AND SIMILAR ELEMENTS.
CL2008000476S1 (en) DEODORIZING DEVICE.
CL2008000400S1 (en) DEODORIZING DEVICE.
CL2007002339S1 (en) DEODORIZING DEVICE.